American Society of Hirudotherapy

Investigation of the therapeutic effects of medicinal leech treatment on lower extremity ischemia-reperfusion injury

Unal K, Samur B, Sharif A, Ibrahimkhanli L, Yumusak N (2026) · Journal of Complementary & Integrative Medicine · n=18

Preclinical / molecular study: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Study Profile

Model / material
experimental preclinical animal study with 18 Wistar Albino rats randomly assigned to three groups: Sham (n=6), Ischemia/Reperfusion (I/R, n=6), and Medical Leech Treatment (MLT, n=6); I/R induced via femoral artery atraumatic vascular clamp; MLT applied to the gastrocnemius muscle region post-I/R; outcomes evaluated by histopathological scoring (edema, degeneration, necrosis, inflammation) and serum/tissue biochemistry (Faculty of Medicine, Gazi University, Ankara, and Faculty of Veterinary Medicine, Harran University, Turkiye)
Sample (n; animals, specimens or isolates)
18
Method
Medicinal leech therapy applied to the gastrocnemius muscle region of each rat following femoral artery ischemia/reperfusion induction; outcomes assessed via histopathological scoring and biochemical analysis of IL-6, SOD, CGRP, NO, TNF-alpha, HIF-1alpha, IMA, GPx, CAT, and EDN-1 in serum and tissue
Main result
Histopathological scores for edema, degeneration, necrosis, and inflammation were significantly lower in the MLT arm compared to the I/R group (p<0.001); biochemical analysis of inflammatory cytokines, oxidative stress markers, and vasoactive mediators (IL-6, SOD, CGRP, NO, TNF-alpha, HIF-1alpha, IMA, GPx, CAT, EDN-1) showed no statistically significant differences across groups; despite biochemical findings, the histopathological signal was robust and suggestive of clinical therapeutic effect

Key Findings

  • Significant histopathological protection (edema, degeneration, necrosis, inflammation; p<0.001) from medicinal leech therapy in a rat I/R model
  • Provides preclinical signal for limb-ischemia and reperfusion-injury indications beyond microsurgical flap salvage
  • Adds Gazi University (Ankara) preclinical research program to the leech-ischemia-protection literature
  • Histopathological signal robust despite absence of significant biochemical differences in inflammatory/oxidative markers
  • Translational rationale for further investigation of MLT in acute and chronic limb ischemia

Limitations

  • Preclinical animal study only - no direct clinical translation
  • Small sample size (n=6 per arm) limits statistical power
  • Inconsistency between histopathological signal and biochemical findings — mechanism unclear
  • Specific bioactive compounds responsible for protective effect not identified
  • Single I/R model (femoral artery clamp) - generalizability to other ischemia models untested

Clinical Implications

Unal 2026 provides preclinical signal that medicinal leech therapy protects against histopathological lower-extremity ischemia/reperfusion injury in a rat femoral artery model. For US clinicians, the trial does not change current clinical practice but adds to the growing preclinical literature supporting investigation of MLT for limb-ischemia indications (acute limb ischemia, reperfusion injury, chronic critical limb ischemia). The biochemical mechanism remains unclear and substantial mechanism work and clinical translation would be required. The trial is included to document the active preclinical translational research program and is hypothesis-generating only.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.